Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

0.7790 +0.0290 (+3.87%)
Streaming Delayed Price Updated: 1:44 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Heron Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Heron (HRTX) Q4 2025 Earnings Call Transcript ↗
Heron (HRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlook ↗
Via Chartmill
News headline image
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
Heron Therapeutics Inc. (NASDAQ: HRTX) Near the Top of Equities by Percentage Gain on 4/23
Via Investor Brand Network
News headline image
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Mixed Q3 2025 Results, Misses Revenue and Earnings Estimates ↗
Heron Therapeutics reported mixed Q3 2025 results, missing revenue and earnings estimates. Despite strong growth from its Acute Care products, the miss led to a negative market reaction. 
Via Chartmill
News headline image
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Heron (HRTX) Q2 Acute Care Jumps 56% ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Top 3 Health Care Stocks That May Crash In May ↗
 
Via Benzinga
News headline image
HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
HRTX stock results show that Heron Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday? ↗
Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.